10% Off
Almitan6.25 mg
Opsonin Pharma Ltd.
৳22.50
Add to cart
Best PriceTk 22.57/piece
1
Alternatives
Price
Medicine overview
Indications of Altrip 6.25 mg
Altrip 6.25 mg is prescribed to treat the acute headache phase of migraine attacks with or without aura. Altrip 6.25 mg is the only oral triptan approved in the USA for the treatment of migraine in adolescent from 12 to 17 years of age.
Theropeutic Class
5-HT Agonists
Pharmacology
Altrip 6.25 mg is a selective and potent serotonin (5-hydroxytryptamine 1B/1D) agonist. Altrip 6.25 mg binds to specific serotonin receptors on meningeal arteries inhibiting the release of vasoactive peptides and causing constriction of the arteries. It has a limited effect on arteries supplying blood to the brain and little effect on cardiac and pulmonary vessels.
Dosage & Administration of Altrip 6.25 mg
Acute Treatment of Migraine Attacks: The recommended dose of Altrip 6.25 mg in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. If the headache is relieved after the initial Altrip 6.25 mg malate dose but returns, the dose may be repeated after 2 hours. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four migraines in a 30-day period has not been established.Hepatic Impairment: The recommended starting dose of Altrip 6.25 mg malate in patients with hepatic impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour periodRenal Impairment: The recommended starting dose of Altrip 6.25 mg malate in patients with severe renal impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period
Dosage of Altrip 6.25 mg
Acute Treatment of Migraine Attacks: The recommended dose of Altrip 6.25 mg in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. If the headache is relieved after the initial Altrip 6.25 mg malate dose but returns, the dose may be repeated after 2 hours. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four migraines in a 30-day period has not been established.Hepatic Impairment: The recommended starting dose of Altrip 6.25 mg malate in patients with hepatic impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour periodRenal Impairment: The recommended starting dose of Altrip 6.25 mg malate in patients with severe renal impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period
Interaction of Altrip 6.25 mg
These drugs have been reported to cause prolonged vasospastic reactions. Cases of life-threatening serotonin syndrome have been reported during combined use of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs).
Contraindications
As with other 5-HT1B/1D receptor agonists, Altrip 6.25 mg should not be used in patients with a history, symptoms or signs of ischaemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal's angina) or severe hypertension and uncontrolled mild or moderate hypertension. Concomitant administration with ergotamine, ergotamine derivatives (including methysergide) and other 5-HT1B/1D agonists is contraindicated.
Side Effects of Altrip 6.25 mg
Serious cardiac reactions, including myocardial infarction, have occurred following the use of Altrip 6.25 mg malate Tablets. These reactions are extremely rare and most have been reported in patients with risk factors predictive of CAD (Coronary Artery Disease).
Pregnancy & Lactation
Pregnancy Category C. There is no data regarding excretion of Altrip 6.25 mg in human milk.
Precautions & Warnings
Hypersensitivity to the active substance or to any of the excipients. Patients with severe hepatic impairment, with a previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA) Peripheral vascular disease.
Storage Conditions
Keep below 30° C temperature in a dry place. Protected from light. Do not freeze. Keep out of the reach of children.
Drug Classes
5-HT Agonists
Mode Of Action
Altrip 6.25 mg is a selective and potent serotonin (5-hydroxytryptamine 1B/1D) agonist. Altrip 6.25 mg binds to specific serotonin receptors on meningeal arteries inhibiting the release of vasoactive peptides and causing constriction of the arteries. It has a limited effect on arteries supplying blood to the brain and little effect on cardiac and pulmonary vessels.
Pregnancy
Pregnancy Category C. There is no data regarding excretion of Altrip 6.25 mg in human milk.
Frequently Asked Questions
What is Altrip 6.25 mg used for?
Altrip 6.25 mg is prescribed to treat the acute headache phase of migraine attacks with or without aura. Altrip 6.25 mg is the only oral triptan approved in the USA for the treatment of migraine in adolescent from 12 to 17 years of age.
What is the dosage of Altrip 6.25 mg?
Acute Treatment of Migraine Attacks: The recommended dose of Altrip 6.25 mg in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. If the headache is relieved after the initial Altrip 6.25 mg malate dose but returns, the dose may be repeated after 2 hours. The maximum daily dose should not exceed 25 mg. The safety of…
What are the side effects of Altrip 6.25 mg?
Serious cardiac reactions, including myocardial infarction, have occurred following the use of Altrip 6.25 mg malate Tablets. These reactions are extremely rare and most have been reported in patients with risk factors predictive of CAD (Coronary Artery Disease).
Who should not take Altrip 6.25 mg?
As with other 5-HT1B/1D receptor agonists, Altrip 6.25 mg should not be used in patients with a history, symptoms or signs of ischaemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal's angina) or severe hypertension and uncontrolled mild or moderate hypertension. Concomitant administration with ergotamine, ergotamine derivatives (including methysergi…
What precautions should be taken with Altrip 6.25 mg?
Hypersensitivity to the active substance or to any of the excipients. Patients with severe hepatic impairment, with a previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA) Peripheral vascular disease.
Is Altrip 6.25 mg safe during pregnancy and breastfeeding?
Pregnancy Category C. There is no data regarding excretion of Altrip 6.25 mg in human milk.
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.